Ex-Moderna CSO resurfaces at PureTech after unexpected departure

Boston

The departure of Joseph Bolen from Moderna Therapeutics as its CSO last year, as well as other subsequent high-profile exoduses, has caused much speculation about the health of this ambitious biotech unicorn.

Now, Bolen is back as the CSO of PureTech Health, a venture firm that has since morphed a bit over the years into a publicly listed therapeutic discovery and development company. He first joined PureTech late last year.

There, he will lead the work on PureTech’s pipeline, which focuses on immune, nervous and gastrointestinal systems and includes more than 20 ongoing clinical trials. PureTech has 5 candidates that are in proof-of-concept studies, as well as multiple pivotal data readouts in the next couple of years.

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

“PureTech Health is one of the most exciting companies in biotech, advancing truly unique multi-modal solutions to some of today’s most significant healthcare challenges through modulation of the human nervous and immune adaptive systems,” Bolen said in a statement. “Our mission at PureTech Health is to collaborate broadly with biomedical science and technology leaders in order to generate the most exciting ideas and then to transform these concepts into breakthrough medicines.”

In this new role, Dr. Bolen will lead the scientific development and advancement of PureTech’s pipeline and will work closely with the team and Scientific Advisory Board as the company identifies and pursues new modalities to address significant medical needs.

Bolen held the position of CSO with Moderna for only 10 months, departing in October 2015. He started out at the Cambridge, MA-based company as its president of R&D; he held that spot for a little over a year and a half. Prior to that, he had been the CSO at Millennium Pharmaceuticals for 14 years. Millennium was acquired by Takeda in 2008 for $8.8 billion.

“Joe is a seasoned industry expert who brings the ideal balance of rigor and creativity to the role of CSO, and shares our vision for identifying and nurturing innovation that can potentially redefine healthcare,” said PureTech CEO Daphne Zohar.

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.